Biotech Millionaire is a premium newsletter focused on small-cap medical biotech stocks with exceptional short- to mid-term profit potential. Their unique C.A.S.H. investing formula—Catalyst, Addressable Market, Science, Hype Potential—ensures that only the most promising candidates make it into the Biotech Millionaire portfolio. They also feature pre-revenue companies with promising pipeline candidates in clinical trials, with the goal for each portfolio stock to get at least a 100% return in the span of 12 to 24 months. Editor Chris Wood also edits the “entry level” healthcare investment advisory Healthy Returns.
Upon subscription, Biotech Millionaire will provide you with: